On this page Agenda Applications for consideration at this meeting 1449 Genetic testing for Alport syndrome 1452 Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma 1453 PD-L1 testing for access to pembrolizumab in patients with unresectable mesothelioma 1454 Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment 1457 PD-L1 (Programmed Death 1 Ligand) IHC (immunohistochemistry) testing for access to pembrolizumab as first-line therapy for patients with unresectable or metastatic bladder cancer ineligible for cisplatin-based therapy 1458 Non-Invasive Prenatal Testing (NIPT) 1460 Blue-light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC) 1461 Non-invasive prenatal testing for common trisomies (21, 18 and 13) Related information Committee: PICO Advisory Subcommittee (PASC)